Introduction#
Evotec SE, a life science company based in Hamburg, Germany, has announced the nomination of Dr. Wolfgang Hofmann for election to its Supervisory Board. This decision will be presented at the company's Annual General Meeting (AGM) scheduled for June 11, 2026.
Board Expansion and Cooperation Agreement#
The AGM agenda will also include the nomination of Dieter Weinand as Chairman of the Supervisory Board and a proposal to increase the board's size from six to seven members. Additionally, Evotec has entered into a cooperation agreement with MAK Capital Fund LP, a shareholder, which includes commitments for voting and collaboration, although specific details were not disclosed.
Importance of the Nomination#
Prof. Dr. Iris Löw-Friedrich, Chairwoman of Evotec’s Supervisory Board, emphasized that Hofmann’s nomination would bring valuable industry, scientific, and governance expertise to the board. Michael A. Kaufman, CEO of MAK Capital, expressed support for Hofmann’s nomination and looks forward to ongoing collaboration with Evotec’s boards.
Recent Financial Performance and Leadership Changes#
Evotec, which focuses on drug discovery and development, reported revenue of €253 million and an adjusted EBITDA of €58 million for the fourth quarter of 2025, meeting expectations despite a tough market. The company has also announced leadership changes, appointing Claire Hinshelwood as the new Chief Financial Officer and Dr. Ingrid Müller as Chief Operating Officer, both effective May 1, 2026. These changes come as the company navigates a challenging financial landscape, with its stock down 30% over the past year.